Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to research presented today at the 2017 Multidisciplinary Thoracic Cancers Symposium.
Analysis of the largest American cancer database indicates that racial disparities persist in the treatment and outcomes of patients diagnosed with stage I non-small cell lung cancer (NSCLC).
The genetic mutations underlying treatment resistance in non-small cell lung cancer (NSCLC) are more complex and dynamic than previously thought.
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects.
Results from a prospective clinical trial showed that a blood test looking at specific biomarkers was able to detect recurrences of lung cancer an average of six months before conventional imaging methods found evidence of recurrence.
An advanced form of image-guided radiation therapy, known as intensity modulated proton therapy, has shown early promise for the treatment of recurrent lung cancer, according to new research from The University of Texas MD Anderson Cancer Center.
New research led by a radiation oncologist at Roswell Park Cancer Institute indicates that less may be more when it comes to some forms of radiation therapy for cancer.
After evaluating more than 900 differences in the shape and structure of cancer cells, UT Southwestern Medical Center researchers developed a computer model able to predict the most deadly lung cancers based on a fraction of those features.
Treating the brain with a preventative course of radiation may help Small Cell Lung Cancer (SCLC) patients - whose tumors often spread to their brain -- live longer, according to a new study from researchers in the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania.
Elderly non-small cell lung cancer (NSCLC) patients undergoing definitive radiation have a lower incidence of esophagitis compared to younger patients and tolerate aggressive standard treatment regimens.
The Addario Lung Cancer Medical Institute, the Bonnie J. Addario Lung Cancer Foundation and Scancell Holdings PLC today announce a collaboration to evaluate the use of Scancell's second innovative cancer vaccine, SCIB2, from its ImmunoBody platform to treat non-small cell lung cancer.
Patients who experience anxiety and depression after being diagnosed with advanced lung cancer are more likely to die sooner, according to new research from the University of British Columbia and BC Cancer Agency.
Cancer is caused by an accumulation of genetic changes in a cell, that overcome the normal checks and balances leading to uncontrolled growth. A complex, interacting network of proteins controls all of a cell's processes, from metabolism to growth and division.
The discovery of several different subtypes of Non Small Cell Lung Cancer (NSCLC), the most frequent form of lung cancer, has been a major breakthrough in the fight against the leading cause of cancer-related death worldwide.
Non-small cell lung cancer patients with advanced disease receiving standard of care treatment have a higher overall survival than similar patients not receiving treatment.
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.
A new Yale study suggests that patients with a common form of lung cancer may still benefit from delayed chemotherapy started up to four months after surgery, according to the researchers.
A new study suggests patients who recover slowly from non-small-cell lung cancer (NSCLC) surgery may still benefit from delayed chemotherapy started up to four months after surgery, according to a new study published online by JAMA Oncology.
Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.